Nevermind the $200 Genome, Element CEO Molly He Says Core Chemistry Capable of Much More

"We’re not a sequencing company," says Molly He, CEO and co-founder of Element Biosciences in our first interview with the leader of the hot new sequencing company which seemed to come out of nowhere this past year. “We’re a biology company.”

Not a sequencing company? Element has just taken the lead in the race toward cheap clinical genomes, and their CEO is putting that news aside in today’s interview. Instead, she’s much more interested in touting the company’s core technology “avidity.” The term comes from a core reagent the company has labeled an “avidite.”

This is a public episode. If you’d like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe